Zingerone improves the immune responses in an animal model of breast cancer.

Abstract

The potent anti-tumorigenic effects were attributed to ginger and there are some reports regarding the anti-cancer and immunomodulatory properties ginger-derived components. This study aimed to investigate the effects of zingerone on some immune-related parameters in an animal model of breast cancer. The breast cancer was established in female BALB/c mice using a carcinogenic 4T1 cell line. At day 10 after cancer induction, tumor-bearing mice were divided into five groups and treated intraperitoneal (daily from days 11-30) with saline or zingerone (at doses 10, 20, 50 and 100mg/kg/day). The mice were sacrificed on day 31 and the number of splenic Th1- and Treg cells, the expression of IFN-γ and TGF-β in the blood mononuclear cells, the antibody production against sheep red blood cell (SRBC) were determined using flow cytometry, real time-PCR and a standard hemagglutination assay, respectively. Zingerone at doses 50 and 100mg/kg enhanced the number of splenic Th1 cells (p<0.03 and 0.007, respectively); at doses 10, 20, 50 and 100mg/kg reduced the number of splenic Treg cells (p<0.02, 0.01, and 0.01, respectively), at doses 50 and 100mg/kg enhanced the expression of IFN-γ (p<0.03), at doses 50 and 100mg/kg reduced the expression of TGF-β, at doses 50mg/kg reduced the titer of anti-SRBC antibody (p<0.05). Zingerone improve the T cell-mediated and antibody responses in a mouse model of breast cancer. Theimmunotherapeutic potentials of zingerone in cancers need more considerations.